The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Reduced Risk of Colorectal Cancer among Long-Term Users of Aspirin and Nonaspirin Nonsteroidal Antiinflammatory Drugs
Abstract
Use of nonsteroidal antiinflammatory drugs (NSAIDs) has been associated with a reduced risk of colorectal cancer, but limited information is available on the effect of individual nonaspirin NSAIDs. In addition, the dose-response relation of aspirin in reducing the risk of colorectal cancer has not been described. We carried out a population-based cohort study with secondary case-control analysis to determine the association between the risk of colorectal cancer and use of aspirin and individual NSAIDs, including the role of dose and duration. The General Practice Research Database in the U.K. was the source population. We traced 943,903 persons 40-79 years of age and free of cancer and colorectal adenoma between January 1994 and September 1997. A total of 2,002 incident cases of colorectal cancer were ascertained. The incidence rate of colorectal cancer per 10,000 person-years was 7.3. The risk of colorectal cancer was reduced in users of nonaspirin NSAIDs and became evident after 6 months of continuous treatment. The adjusted relative risk was 0.5 (95% confidence interval = 0.4-0.7). The reduction in risk disappeared completely 1 year after stopping NSAID treatment. The risk of developing colorectal cancer was reduced in long-term users of aspirin at doses of 300 mg daily (relative risk = 0.6; 95% confidence interval = 0.4-0.9). Daily doses of 75 and 150 mg aspirin were not associated with a reduced risk of colorectal cancer. Our data support the existence of an important protective effect of nonaspirin NSAID continuous intake against colorectal cancer and point to a similar reduction in risk for aspirin at doses of at least 300 mg daily. One-year treatment with NSAIDs would prevent one case of colorectal cancer in a population of 1,000 persons 70-79 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Much data indicates that use of these drugs reduces colon cancer risk by 40–50%”
From Inflammation and cancer (2002) · cites this paper as [58]
In the citing paper
“and may be preventative for lung, oesophagus and stomach cancer57,58.”
From Inflammation and cancer (2002) · cites this paper as [58]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Aramandla, R., Giardiello, F. M., Ferrenbach, S., & DuBois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,512
Aspirin and the Risk of Colorectal Cancer in Women
Giovannucci, E. L., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., Willett, W. C., & Speizer, F. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331001 · Cited by 1,095
Aspirin use and risk of fatal cancer.
Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., & Heath, C. W. (1993) · PubMed · Cited by 870
Jick, H., Jick, S. S., & Derby, L. E. (1991) · BMJ · doi:10.1136/bmj.302.6779.766 · Cited by 839
Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals
Giovannucci, E. L., Rimm, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., & Willett, W. C. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-4-199408150-00001 · Cited by 784
Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study
Schreinemachers, D. M., & Everson, R. B. (1994) · Epidemiology · doi:10.1097/00001648-199403000-00003 · Cited by 738
Kune, G. A., Kune, S., & Watson, L. F. (2007) · International Journal of Epidemiology · doi:10.1093/ije/dym193 · Cited by 654
Incidence of Cancer Among Patients With Rheumatoid Arthritis
Gridley, G., McLaughlin, J. K., Ekbom, A., Klareskog, L., Adami, H., Hacker, D. G., Hoover, R. N., & Fraumeni, J. F. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.4.307 · Cited by 580
Prophylactic aspirin and risk of peptic ulcer bleeding
Weil, J., Colin-Jones, D. G., Langman, M. J. S., Lawson, D. H., Logan, R., Murphy, M. S., Rawlins, M. D., Vessey, M. P., & Wainwright, P. (1995) · BMJ · doi:10.1136/bmj.310.6983.827 · Cited by 563
Research works printed but not linked: 4
- Vainio, 1997, Cancer Epidemiol Biomarkers Prev, 6, 749
- Kune, 1988, Cancer Res, 48, 4399
- Reeves, 1996, Cancer Epidemiol Biomarkers Prev, 5, 955
- Thun, 1993, Cancer Res, 53, 1322
Cited by
Sorted by citations
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,430
Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E. D., Keresztes, R. S., Petrelli, N. J., Pipas, J. M., Karp, D. D., Loprinzi, C. L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021633 · Cited by 1,133
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105
Metadata
- Authors
- García Rodríguez, L. A., & Huerta-Alvarez, C.
- Venue
- Epidemiology
- Published
- 2001-01
- Volume
- 12
- Issue
- 1
- Pages
- 88-93
- ISSN
- 1044-3983 (ISSN-L)
- OpenAlex
- W1971370481
- Cited by
- 359
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 8 · 2022: 4 · 2021: 5 · 2020: 11 · 2019: 6 · 2018: 11 · 2017: 10 · 2016: 16 · 2015: 15 · 2014: 11 · 2013: 14 · 2012: 19
- FWCI
- 16.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Epidemiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, aspirin, nonsteroidal anti-inflammatory drugs, chemoprevention, dose-response relationship, long-term drug use, cancer incidence, colorectal adenoma
- MeSH terms
- Adenoma, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Female, United Kingdom, Humans, Male, Middle Aged, Risk Factors, Colorectal Neoplasms, Cohort Studies, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
